The Nucleic Acid Therapeutics CDMO Market in 2026 includes a substantial and growing antisense oligonucleotide manufacturing segment, where the commercial success of approved ASO drugs including nusinersen for spinal muscular atrophy, eteplirsen for Duchenne muscular dystrophy, and inotersen and patisiran for transthyretin amyloidosis has validated the clinical and commercial viability of oligonucleotide therapeutics and generated a growing pipeline of ASO candidates requiring GMP synthesis services at scales ranging from gram quantities for early clinical trials to multi-kilogram quantities for commercial supply of rare disease products with large patient populations.

Solid-phase oligonucleotide synthesis on automated synthesizer platforms scales from milligram research quantities to kilogram commercial quantities through incremental increases in synthesis column scale, with commercial ASO manufacturing utilizing large-scale synthesis columns from suppliers including Kiloton Therapeutics and contract synthesis organizations that have invested in kilogram-scale column infrastructure capable of producing multi-kilogram ASO batches. The synthesis cycle involves sequential addition of phosphoramidite nucleotide building blocks with each cycle's coupling efficiency directly determining the fraction of full-length product in the crude synthesis mixture, making coupling efficiency optimization and building block quality control critical determinants of manufacturing yield and purification requirements.

Purification of synthetic oligonucleotides from the complex mixture of full-length product, truncated failure sequences, and chemical modification byproducts generated during solid-phase synthesis requires high-performance chromatography at preparative scale, typically using ion-exchange or reverse-phase HPLC purification that achieves the high-purity specifications required for pharmaceutical applications. The scale-up of HPLC purification from analytical to preparative to production scale is a major capital investment for oligonucleotide CDMOs, with kilogram-scale oligonucleotide purification requiring large-bore preparative HPLC columns and associated pump, detector, and fraction collection infrastructure that represents millions of dollars of specialized equipment investment.

Chemical modification strategies applied to therapeutic ASOs to improve metabolic stability, tissue distribution, and target binding affinity — including phosphorothioate backbone substitution, two-prime methoxyethyl, two-prime-O-methyl, and locked nucleic acid ribose modifications, and various conjugation approaches for tissue targeting — require specialized phosphoramidite building block synthesis or procurement and validated synthesis cycle modifications that differ from standard DNA oligonucleotide synthesis, creating formulation development service value for CDMOs with expertise in modified nucleotide chemistry beyond standard synthesis capabilities.

The rare disease focus of many approved and investigational ASO programs creates distinctive commercial manufacturing considerations including small patient populations requiring modest commercial supply volumes that may not justify large-scale dedicated manufacturing, the importance of supply continuity assurance for patients with life-threatening diseases without alternative treatments, the potential for accelerated regulatory timelines through orphan drug designation that compresses the development timeline between clinical phase and commercial launch, and reimbursement negotiations at very high per-patient price points that generate substantial revenue from modest commercial manufacturing volumes.

Do you think antisense oligonucleotide manufacturing will continue requiring specialized CDMO expertise or will the maturity of solid-phase synthesis technology eventually enable broader access to oligonucleotide manufacturing capability that reduces CDMO pricing power in this market segment?

FAQ

• What chemical modifications are most commonly incorporated into therapeutic antisense oligonucleotides and what manufacturing process changes do these modifications require? Phosphorothioate backbone modification replacing one non-bridging oxygen with sulfur at each internucleotide linkage is the most universal modification improving nuclease resistance, with sulfurization achieved through oxidation step replacement with sulfurization reagents including Beaucage reagent or DDTT during synthesis cycle, while two-prime-methoxyethyl and two-prime-O-methyl ribose modifications require corresponding modified phosphoramidite building blocks incorporated at specified sequence positions, and locked nucleic acid modifications using bridged ribose analogs require LNA phosphoramidites from specialized suppliers with higher per-nucleotide cost than standard DNA or RNA phosphoramidites, with these modifications individually manageable in standard synthesizers but their combination in gapmer ASO designs requiring careful synthesis cycle optimization balancing coupling efficiency with modified nucleotide reactivity characteristics.

• How do CDMOs manage the intellectual property and confidentiality considerations of oligonucleotide sequence manufacturing where sequence information is the core proprietary asset of the drug developer client? Oligonucleotide CDMO confidentiality management requires comprehensive non-disclosure agreements protecting client sequence identity, synthesis parameters, and analytical method information from disclosure to competing clients or third parties, physical manufacturing segregation ensuring client oligonucleotide synthesis occurs in dedicated campaign manufacturing without co-mingling with other clients' materials, electronic data security measures restricting sequence database access to personnel directly involved in client manufacturing projects, and contractual provisions governing CDMO employees' confidentiality obligations that survive employment termination, with some CDMOs offering dedicated manufacturing suites or equipment for highest-sensitivity programs where even incidental personnel overlap with other client programs creates competitive intelligence risk for clients concerned about synthesis capability revelation through CDMO staff interactions.

#NucleicAcidTherapeuticsCDMO #AntisenseOligonucleotides #OligonucleotideSynthesis #RareDiseaseDrugs #PharmaceuticalManufacturing #CDMOmarket